Quick Answer
Niacin Exercise Performance Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT).
Key Takeaways
- 01Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT). [Wan Q (2026)]
- 02Moderate-intensity aerobic and resistance exercise consistently improved maximal oxygen uptake (VO 2 max), maximal workload (W max), muscle strength, and mitochondrial enzyme activity, with no consistent group-level increases observed in creatine kinase (CK) levels or mtDNA mutation burden. [Wan Q (2026)]
- 03Aerobic training enhanced oxidative capacity, phosphocreatine (PCr) recovery, and antioxidant defense, while resistance training improved muscle strength, satellite cell activation, and reduced cytochrome c oxidase (COX)-deficient fibers. [Wan Q (2026)]
- 04Background Mitochondrial myopathy (MM) is a group of rare, progressive muscle disorders characterized by impaired oxidative phosphorylation due to mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutations, leading to exercise intolerance, muscle weakness, and metabolic dysfunction. [Wan Q (2026)]
The current Migaku evidence database contains 2 reusable source documents for Niacin Exercise Performance Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT). [Wan Q (2026); evidence level 1]
- Moderate-intensity aerobic and resistance exercise consistently improved maximal oxygen uptake (VO 2 max), maximal workload (W max), muscle strength, and mitochondrial enzyme activity, with no consistent group-level increases observed in creatine kinase (CK) levels or mtDNA mutation burden. [Wan Q (2026); evidence level 1]
- Aerobic training enhanced oxidative capacity, phosphocreatine (PCr) recovery, and antioxidant defense, while resistance training improved muscle strength, satellite cell activation, and reduced cytochrome c oxidase (COX)-deficient fibers. [Wan Q (2026); evidence level 1]
- Background Mitochondrial myopathy (MM) is a group of rare, progressive muscle disorders characterized by impaired oxidative phosphorylation due to mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutations, leading to exercise intolerance, muscle weakness, and metabolic dysfunction. [Wan Q (2026); evidence level 1]
- Biomarkers may be useful to overcome intrinsic challenges associated with clinical trial designs in small populations that are both genetically and clinically heterogenous and may facilitate early drug development by guiding dose selection and trial enrichment. [Stern Sydney (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources